✦ LIBER ✦

Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

✍ Scribed by Mickisch, G H J; Escudier, B; Walzer, S; Nuijten, M

Book ID: 110000670
Publisher: Nature Publishing Group
Year: 2010
Tongue: English
Weight: 159 KB
Volume: 103
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6605887

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Costs of managing adverse events in the

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

✍ Mickisch, G; Gore, M; Escudier, B; Procopio, G; Walzer, S; Nuijten, M 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 356 KB

Regarding: ‘Costs of managing adverse ev

Regarding: ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’

✍ Porta, C 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 97 KB

Comment on ‘Costs of managing adverse ev

Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’

✍ Charbonneau, C; Sandin, R 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 155 KB

Recombinant interferon α-2A combined wit

Recombinant interferon α-2A combined with prednisone in metastatic renal-cell carcinoma: Treatment results, serum interferon levels and the development of antibodies

✍ Sophie D. Fosså; Gustav Lehne; Ragnhild Gunderson; Unni Hielmaas; Eduard E. Hold 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 French ⚖ 375 KB 👁 1 views

Five partial responses were seen in 23 patients with metastatic renal-cell carcinoma (MRCC) receiving interferon-a 2a (IFN) + prednisone (P). Four of 24 subsequent patients responded to IFN + P (combined response rate 19%). The median response duration was 8 months (3 to 30 months). The one-year sur

Phase II trial of continuous once-daily

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma

✍ Carlos H. Barrios; David Hernandez-Barajas; Michael P. Brown; Se-Hoon Lee; Luis 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 855 KB

Subcutaneous interleukin-2 and interfero

Subcutaneous interleukin-2 and interferon α in the treatment of patients with metastatic renal cell carcinoma—Less efficacy compared with intravenous interleukin-2 and interferon α : Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie

✍ Alain Ravaud; Rémy Delva; Fréderic Gomez; Christine Chevreau; Jean-Yves Douillar 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

## Background: The main objective of this trial was to evaluate the combination of subcutaneous (sc) interleukin-2 (il-2) with interferon alpha-2a (ifn-alpha) in the treatment of patients with metastatic renal cell carcinoma (mrcc) compared with a previous trial that used continuous-infusion il-2 a